All articles tagged with #personalized vaccine
A phase 1 trial at Siteman Cancer Center shows a personalized neoantigen DNA vaccine (GNOS-PV01) for glioblastoma is safe and elicits robust immune responses; among nine patients, about two-thirds had no progression at six months and two-thirds were alive at one year, including a long-term recurrence-free survivor, indicating potential benefit and the need for larger trials.
At the AACR meeting, researchers report a phase 1 trial of a patient-specific mRNA vaccine for pancreatic cancer, made from each patient's tumor material after surgery and used with immunotherapy and chemotherapy. Eight patients showed immune responses, and seven of these responders were alive up to six years post-surgery, with about 90% of responders remaining alive at follow-up. While promising, the findings come from a small early trial, and a global phase 2 study is now underway to assess broader efficacy.
A small Memorial Sloan Kettering study finds a patient-specific mRNA vaccine for pancreatic cancer can provoke strong immune responses and deliver long-term survivors, despite a turbulent year of funding and public skepticism around mRNA. Eight of 16 patients had a meaningful immune response and seven are alive six years after the trial; larger multisite trials and industry backing are advancing the approach, which also includes non-personalized, off-the-shelf vaccines aiming to trigger broader anti-tumor immunity.
After a turbulent year for funding and public trust, early-stage trials of mRNA cancer vaccines—including a personalized vaccine for pancreatic cancer—are showing strong immune responses and potential long-term benefit, with larger multisite trials and renewed NIH/NCI support underway, though funding and skepticism remain challenges.